{"id":14130,"date":"2025-01-29T15:22:44","date_gmt":"2025-01-29T20:22:44","guid":{"rendered":"https:\/\/www.biotech.ca\/?p=14130"},"modified":"2025-01-29T15:22:46","modified_gmt":"2025-01-29T20:22:46","slug":"accords-bilateraux-pour-les-medicaments-pour-le-traitement-des-maladies-rares","status":"publish","type":"post","link":"https:\/\/www.biotech.ca\/fr\/news\/accords-bilateraux-pour-les-medicaments-pour-le-traitement-des-maladies-rares\/","title":{"rendered":"Accords bilat\u00e9raux pour les m\u00e9dicaments pour le traitement des maladies rares"},"content":{"rendered":"\n<p>BIOTECanada salue les progr\u00e8s continus du gouvernement du Canada vers l\u2019atteinte d\u2019accords bilat\u00e9raux avec l\u2019Ontario, le Nouveau-Brunswick, la Saskatchewan, l\u2019Alberta, Terre-Neuve-et-Labrador et la Colombie-Britannique visant \u00e0 am\u00e9liorer l\u2019acc\u00e8s aux m\u00e9dicaments pour les maladies rares, \u00e0 acc\u00e9l\u00e9rer le diagnostic et \u00e0 bonifier le d\u00e9pistage. Cette collaboration constitue un jalon important pour \u00e9tendre l\u2019acc\u00e8s aux traitements des maladies rares, un enjeu que BIOTECanada continue de d\u00e9fendre. Un investissement continu permettra de pallier les lacunes persistantes dans l\u2019acc\u00e8s aux soins, et d\u2019offrir un acc\u00e8s \u00e9largi aux traitements transformateurs aux Canadiens et aux Canadiennes atteints de maladies rares.<\/p>\n\n\n\n<p>Un acc\u00e8s opportun \u00e0 des traitements transformateurs \u2013 tels que les th\u00e9rapies cellulaire et g\u00e9nique, les biotechnologies et les m\u00e9dicaments pour maladies rares \u2013 n\u00e9cessite la collaboration entre les provinces et l\u2019adoption transparente de politiques efficaces et durables visant \u00e0 r\u00e9pondre aux besoins des patients atteints de maladies rares.<\/p>\n\n\n\n<p>Pour consulter les accords bilat\u00e9raux existants avec les provinces, visitez le&nbsp;:&nbsp;<a href=\"https:\/\/www.canada.ca\/fr\/sante-canada\/organisation\/transparence\/ententes-en-matiere-de-sante\/priorites-partagees-matiere-sante\/accords-bilateraux-pour-medicaments-pour-traitement-maladies-rares.html\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.canada.ca\/fr\/sante-canada\/organisation\/transparence\/ententes-en-matiere-de-sante\/priorites-partagees-matiere-sante\/accords-bilateraux-pour-medicaments-pour-traitement-maladies-rares.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>BIOTECanada salue les progr\u00e8s continus du gouvernement du Canada vers l\u2019atteinte d\u2019accords bilat\u00e9raux avec l\u2019Ontario, le Nouveau-Brunswick, la Saskatchewan, l\u2019Alberta, Terre-Neuve-et-Labrador et la Colombie-Britannique visant \u00e0 am\u00e9liorer l\u2019acc\u00e8s aux m\u00e9dicaments<\/p>\n<p class=\"more-link-box\"><a class=\"more-link button_a arrow\" href=\"https:\/\/www.biotech.ca\/fr\/news\/accords-bilateraux-pour-les-medicaments-pour-le-traitement-des-maladies-rares\/\">Lire la suite<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"rank_math_lock_modified_date":false,"inline_featured_image":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":"","footnotes":""},"categories":[58],"tags":[45],"class_list":["post-14130","post","type-post","status-publish","format-standard","category-declarations","tag-home-fr","entry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/posts\/14130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/comments?post=14130"}],"version-history":[{"count":1,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/posts\/14130\/revisions"}],"predecessor-version":[{"id":14131,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/posts\/14130\/revisions\/14131"}],"wp:attachment":[{"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/media?parent=14130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/categories?post=14130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.biotech.ca\/fr\/wp-json\/wp\/v2\/tags?post=14130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}